When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CERC - Dosing underway in Cerecor's early-stage CERC-007 study in multiple myeloma
Cerecor Inc.
Cerecor (CERC) has dosed its first patient in a Phase 1b clinical trial of CERC-007, a fully human anti-IL-18 monoclonal antibody (mAb) being developed for patients with relapsed or refractory multiple myeloma ((MM)).The study will determine the recommended Phase 2 dose, safety and preliminary efficacy of CERC-007.Initial data are anticipated in Q1 2021.